MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
32.32
+0.85
+2.70%
After Hours: 32.21 -0.11 -0.34% 19:59 05/08 EDT
OPEN
31.71
PREV CLOSE
31.47
HIGH
32.47
LOW
30.91
VOLUME
2.85M
TURNOVER
--
52 WEEK HIGH
36.44
52 WEEK LOW
15.35
MARKET CAP
3.33B
P/E (TTM)
-50.3662
1D
5D
1M
3M
1Y
5Y
1D
Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?
Simply Wall St · 12h ago
A Look At Beam Therapeutics (BEAM) Valuation After Earnings Beat And Positive Clinical Updates
Simply Wall St · 1d ago
JonesResearch upgrades ‘fast-follower’ Korro Bio to Buy
TipRanks · 2d ago
Analysts Conflicted on These Healthcare Names: Monte Rosa Therapeutics (GLUE) and Beam Therapeutics (BEAM)
TipRanks · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Owlet (OWLT)
TipRanks · 2d ago
Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)
TipRanks · 2d ago
Beam Therapeutics (BEAM) Q4 Profit Surprise Challenges Bearish Earnings Narratives
Simply Wall St · 3d ago
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Beam Therapeutics (BEAM)
TipRanks · 3d ago
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.